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Peripheral arterial occlusive disease (PAOD) leads
to insufficient blood supply to the involved muscle,
which is especially aggravated during exercise.1
Consequently, exercise capacity of such patients, for
instance, on a treadmill, is reduced.2,3 However, pre-
vious studies demonstrated that a decrease of exercise
performance does not correlate well with the reduc-
tion of blood supply to the affected lower extremities
in patients with PAOD3,4; furthermore, improvement
of blood flow to the legs by means of medication, vas-
cular surgery, or angioplasty is not always accompa-
nied by an increase in exercise ability.5-9 These facts
suggest that other factors besides the reduced blood
supply may contribute to the reduction of exercise
performance in patients with PAOD.
In patients with PAOD, muscle oxidative enzyme
activities are related to treadmill exercise performance
and metabolic capacities.10,11 Thus the metabolic
changes as result of adaptation to limited blood sup-
ply in affected muscles and detraining effects as result
of disuse and leg pain may be also responsible for the
reduced exercise ability. However, Regensteiner et
al12 and Hiatt et al13 demonstrated that there was a
substantial heterogeneity in muscle enzyme activities
that was not associated with muscle strength. So there
might be additional muscular factors that play a role
in exercise ability in patients with PAOD.
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Purpose: Peripheral arterial occlusive diseases (PAODs) not only compromise blood flow
but lead to a series of subsequent metabolic and structural changes in the relevant mus-
cles. Changes in myofibrillar proteins (eg, of myosin heavy chain [MHC] isoforms), one
of the determinants of muscle structure as well as of muscular function, have not been
reported in patients with PAOD and were therefore the aim of this study.
Methods: Thirteen consecutive patients with PAOD were examined (clinical stage accord-
ing to Fontaine II, three patients; III, three patients, and IV, seven patients) and com-
pared with five age-matched control patients who had been in traffic accidents. A calf
muscle sample (gastrocnemius muscle) in the ischemic region was taken for MHC iso-
form analysis by sodium dodecyl sulfate polyacrylamide gel electrophoresis and silver
stain, and the relative content of MHC isoforms was measured.
Results: Compared with the control patients, there was no significant change of MHC
isoforms in patients with PAOD II. In patients with PAOD III, MHC IIb decreased sig-
nificantly (P < .05) although MHC IIa remained unchanged; in patients with PAOD IV,
both MHC IIa and IIb decreased significantly (P < .05). Accordingly, there was a pro-
gressive increase of the relative amount of MHC I with more critical ischemia in PAOD.
Conclusion: In patients with PAOD, the content of MHC II decreased with a higher
grade of ischemia. That seems to be consistent with an increased resistance to ischemia
for myosin isoforms in the order of I more than in IIa more than IIb. Whether the
decrease of MHC II in patients with PAOD is related to atrophy of muscle fibers or to
muscle-fiber transition must be investigated further. (J Vasc Surg 2000;31:443-9.)
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Muscle dysfunction in PAOD is associated with
histologic signs of muscle fiber denervation.12,14,15
Histologic changes in skeletal muscle in unilateral
PAOD were examined by Regensteiner et al,12 and
muscle fiber atrophy and decrease of the type II fiber
cross-sectional area could be demonstrated in such
patients. Thus the histologic changes of muscles,
especially type II fiber atrophy, may contribute to the
reduced exercise performance in patients with
PAOD.12 Fiber loss and reduced fiber diameter were
observed in patients with PAOD,14,16 and ischemia
seems to result in a greater loss of type II fibers than
type I fibers.17-19 However, there are other studies
that report no clear difference in fiber distribution
and in diameter between diseased and nondiseased
legs of patients with unilateral PAOD.10,20,21
Different study conditions and experimental pro-
cedures may be one cause of the conflicting findings.
Another explanation might be the heterogeneity of
the muscle fiber composition. In fact, muscle fibers
are composed of a series of contractile proteins with
different molecular and biochemical characteris-
tics.22-24 This means, that more than one single
myosin heavy chain (MHC) isoform may exist in a
single fiber as heterogeneity on the fiber level.23-26
Because MHC isoform content determines the
metabolic and contractile properties of muscle
fibers, understanding the changes of MHC isoforms
in skeletal muscles of patients with PAOD may pro-
vide meaningful information about the functional
state of the muscles.
Myosin fiber types are not unchangeable but
dynamic.23,27 Transition of muscle fiber type caused
by changes in myosin isoforms may take place,
depending on muscular adaptation.27,28 Many factors
including energy metabolism,22,29 blood flow,30,31
and exercise load28,32,33 influence the MHC isoforms
and may thereby cause a transition of muscle fiber
types.22,24
Ischemia, denervation, and muscular inactivity
may take place in patients with PAOD, all of which
may cause changes in myosin isoforms that induce
transition of muscle fiber types. However, to date,
there are no available data that report the effect of
PAOD on myosin isoforms. This study investigated
the expression of MHC isoforms in skeletal muscle
of patients with PAOD.
METHODS
Subjects. Eighteen consecutive subjects (six
men, twelve women), aged 67 ± 11 years, were
enrolled in this study after informed consent was
obtained. The study was approved by the ethics
committee of the Medical Faculty of the University
of Ulm. The subjects were patients with PAOD and
age-matched control patients (no PAOD). There
was no difference between control patients and
patients with PAOD regarding age and sex. Patients
with PAOD were diagnosed by clinical examination,
Doppler scan measurement, and arterial angiogra-
phy. In patients with intermittent claudication, a
treadmill test was performed at 12% inclination and
3 km · hour–1 speed, and the painfree walking dis-
tance was measured.34 All patients with PAOD had
diseased legs bilateral, and the more severe side was
used for the classification of PAOD. The classifica-
tion of PAOD follows Fontaine’s criteria. Further
inclusion criteria were that iliacal or femoral arteries
were leading stenoses, that the history of claudica-
tion or leg pain was longer than 6 months, and that
a surgical intervention was indicated. The patients
with PAOD II or III underwent vascular recon-
structive surgery. In patients with PAOD II, surgery
was performed because of no effective medical ther-
apy and isolated single stenosis. In these patients, the
procedure was a transluminal endatherectomy with
patch. Patients with PAOD III underwent
iliofemoral bypass grafting. Patients with PAOD IV
underwent an amputation at the knee level. Patients
with critical ischemic legs (PAOD IV) were not
included if they had reconstructive surgery because
the muscle sample might have increased the trauma
in such patients.
Control patients who were enrolled in the study
were victims of traffic accidents who underwent an
immediate operation because of the general clinical
situation of the patient (eg, bleeding, trauma).
Control patients were examined after surgery and
had palpable pulses and normal Doppler pressures in
the leg. Control patients had no history or clinical
evidence of coronary artery disease or ischemic
stroke and no significant cardiovascular risk factors,
whereas nine of the 13 patients with PAOD had a
history or clinical signs of coronary artery disease. 
Muscle sampling. Samples were taken during
surgery from vital muscle without the use of a ther-
mocauter. All samples were obtained from the gas-
trocnemius muscle, except one sample that was
taken from soleus muscle from a control patient.
About 0.5 g muscle tissue was taken and frozen
immediately in liquid nitrogen and then stored at
–80°C until subsequent analysis.
MHC analysis. About 50 mg of muscle tissue
was removed from the muscle samples, and total
muscle proteins were extracted in 8 volumes of
extraction buffer26 (containing 100 mmol/L
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Na4P2O7 ⋅ 10 H2O, 5 mmol/L EGTA, 5 mmol/L
MgCl2 ⋅ 6H2O, 0.3 mmol KCl, and 1 mmol/L DTT)
with the use of a mechanical homogenizer. The mus-
cle homogenates were stirred on ice for 20 minutes,
then centrifuged at 4°C and 16,000g for 10 minutes.
The supernant was collected and mixed with an equal
volume of glycerol. The total protein concentration
was determined according to Lowry et al.35 Total
protein (1.25 µg) was diluted according to the
method of Laemmli36 and loaded for sodium dode-
cyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE). A discontinuous gel system was used for
SDS-PAGE. Stacking gel (1.5-mm thick) was com-
posed of 4% polyacrylamide, 0.04% bisacrylamide,
125 mmol/L Tris-HCl (pH 6.7), 0.1% SDS, 0.083%
ammonium persulfate, and 0.15% tetramethylethyl-
enediamine (TEMED). Separating gel was composed
of 7.2% acrylamide, 0.072% bisacrylamide, 375
mmol/L Tris-HCl (pH 8.6), 25% glycerol, 0.1%
SDS, 0.043% ammonium persulfate, and 0.17%
TEMED. Electrophoresis was performed at a con-
stant temperature (18°C) at 100 volts and 50 mA for
22 hours in running buffer (pH 8.3) in final concen-
tration: 0.30% Tris, 1.44% glycine, and 0.1% SDS.
Protein detection was performed with silver
staining of the gels according to the method of
Oakley et al.37 The myosin isoforms were identified
with reference to a protein marker (Bio-Rad, 161-
0324; Bio-Rad Laboratories, Hercules, Calif) and
verified by Western blot. The protein bands were
scanned and evaluated by integrating densitometry.
A negative control (loading buffer) was run parallel
to the samples and served as background densito-
metric value, which was subtracted for the individual
values of each sample.
The Western Blot was performed after SDS-
PAGE by transferring proteins to a polyvinylidenflu-
oride membrane, which was incubated with primary
monoclonal antibody against MHCfast (mouse anti-
human anti-IgG, clone MY-32; Sigma Chemical Co,
St Louis, Mo) or MHCslow (mouse anti-human anti-
IgG, Clone NOQ7.5.4D; Sigma Chemical Co) and
then with secondary antibody conjugated with
horseradish peroxidase (goat anti-mouse anti-IgG,
115-035-071; Jackson ImmunoResearch Labora-
tories, West Grove, Pa). The detection of protein
bands followed the standard protocol of enhanced
chemoluminescence (Amersham International plc,
Little Chalfont, Buckinghamshire, England). The
Western blot confirmed that the MHC isoform
bands detected by silver stain were identical to those
that reacted specifically to the corresponding anti-
bodies.
Data analysis. Analyses of the samples were run
in replicate. The percentage of the myosin isoform was
calculated according to the densitometric values of
each myosin isoform band on the gels. The coeffi-
cients of variance of replicates of the same sample for
MHC I, MHC IIa, and MHC IIb were 11.2%, 10.4%,
and 12.1%, respectively. The data are expressed as
mean ± SD, and the differences were tested with an
unpaired Wilcoxon test and assumed to be significant
at P ≤ .05.
RESULTS
The personal data of the subjects and ankle-
brachial-index are shown in Table I. The patients
with PAOD II had a pain-free walking distance of
181 ± 43 m. 
All muscle samples could be successfully ana-
lyzed. Typical silver-stained gels of control patients
and patients with PAOD II, III, and IV are depicted
in Fig 1. 
The control patients had a normal distribution of
MHCs (MHC I, IIa, IIb: 35.8% ± 9.3%, 41.6% ±
7.0%, 22.6% ± 4.5%, respectively; Figs 1 and 2).
There was no significant difference in MHCs
between patients with PAOD II and control
patients. That was true for the absolute MHC iso-
form values and for the ratios of MHC I/II and
MHC IIa/IIb (Table II). 
In patients with PAOD III, significant lower
MHC IIb content was observed (10.2% ± 2.2%).
The percentage of MHC IIa was not changed, and
there was a corresponding significant higher MHC I
percentage (Fig 2). The ratio of MHC IIa/IIb was
increased as expected (Table II). 
Patients with PAOD IV had no further differ-
ence in MHC IIb compared with patients with
PAOD III; the prominent changes were a significant
lower MHC IIa content (28.7% ± 7.2%) and a
remarkably high MHC I content of 62.4% ± 11.1%
(Figs 1 and 2). The ratio of MHC I/II demonstrates
the shift to slower MHCs and the ratio between
MHC IIa/IIb (Table II).
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Table I. Subjects 
Control PAOD II PAOD III PAOD IV
n 5 3 3 7
Age (y) 65 ± 7 67 ± 8 70 ± 6 70 ± 8
Body mass (kg) 72 ± 10 74 ± 7 70 ± 12 73 ± 5
ABI — 0.82 ± 0.21 0.59 ± 0.17 0.36 ± 0.24
ABI, Ankle-brachial index for systolic blood pressure.
DISCUSSION
Previous studies showed that impairment of
muscle function in patients with PAOD was not only
dependent on muscular blood supply but also asso-
ciated with metabolic adaptations and structural
changes, in particular denervation and muscle fiber
composition. Myosin isoforms determine muscle
fiber type and also reflect the functional state of the
ischemic muscle of patients with PAOD. This study
investigated, for the first time, the expression of
MHC isoforms in skeletal muscle of patients with
PAOD and showed a decrease of MHC IIb and
increase of MHC I, followed by a decrease of MHC
IIa with progressive ischemia.
It is known22,24 that the slow muscle fiber I, clas-
sified by actin adenosine triphosphatase-based histo-
chemistry and characterized by lower speed of mus-
cle shortening and higher fatigue resistance, has a
higher capacity of oxidative metabolism than other
fiber types. The main MHC isoform of a slow fiber
is the MHC I. The fast fiber IIb is characteristic of a
high contactility and posseses a high capacity of
anaerobic glycolytic metabolism and mainly consists
of MHC IIb. The interim of both these fibers, IIa,
with moderate contractile activity and oxidative
metabolism, contains mainly MHC IIa. However,
the histochemically based classified fiber types are
not always in accordance to the MHC iso-
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Fig 1. An example of MHC isoforms analyzed by SDS-PAGE. Lanes 1 through 4 represent
muscle samples from a control patient and from patients with PAOD II, III and IV, respec-
tively. Each protein band was measured densitometrically and expressed as a percentage, tak-
ing all bands of a sample as 100%.
Fig 2. MHC isoform distribution between control patients and patients with PAOD with clin-
ical stage II, III, IV. In comparison with control patients, there was no change of MHC iso-
forms in patients with PAOD II, but there was a significant decrease of MHC IIb in PAOD
III and IIa and of IIb in PAOD IV.
forms.24,25,33 There is evidence that in a single fiber
different MHC isoforms coexist (for example, a fiber
I may be found in MHC I and IIa; a fast fiber IIb
may be found MHC IIa and IIb). 
Changes of MHC isoforms showed in this study
are not absolute values but relative. The sum of all
MHC isoforms was assumed to be 100%, and a per-
centage was calculated for each of the three iso-
forms. This means that an increase of one MHC iso-
form may indicate either a real increase or a decrease
of the remaining MHC isoforms.24-27 Because
atrophic changes have been demonstrated in skeletal
muscle of patients with PAOD,12,13,15,17,21,38 it can
be speculated that a primary decrease of an MHC
isoform might be the reason for the changes. This
would mean that there was a loss of MHC IIb in
patients with PAOD. Interestingly, in patients with
PAOD II (intermittent claudication), there were no
significant changes in MHC isoforms in comparison
with control patients, although the performance of
these patients was clearly reduced. As the ischemia
became more critical (PAOD III), MHC IIb
decreased, accompanied by an increase of MHC I;
but MHC IIa remained almost unchanged. In
patients with PAOD IV, MHC IIa decreased signif-
icantly without a further significant decrease of IIb.
These results suggest that MHC IIa might be more
resistant to ischemia than MHC IIb.
Although there seems to be no study reported
regarding MHC isoforms in patients with PAOD,
several studies have dealt with histologic changes in
PAOD and reported a loss of muscle fiber type
II.12,14,15 This might be, to some extent, in accor-
dance with our study, although the muscle fiber type
and the MHC isoforms are not the same. Therefore
these results suggest that muscle fiber II are more
vulnerable to ischemia. The mechanisms leading to
the reduction of MHC II in the relevant muscles of
patients with PAOD may be complicated because
many factors such as age, disuse, metabolic changes,
and especially ischemia are involved in the issue. 
However, it could be hardly distinguished
whether the changes in MHC isoforms are due to
atrophic change (loss) of MHC II or because of
transition from MHC II to MHC I. It was demon-
strated that type II fibers are more vulnerable to
reduced energy content.18 In patients with PAOD, a
decrease in muscle fiber type II cross-sectional area
was found,12 and fiber loss and reduced fiber diam-
eter have also been observed in patients with
PAOD.15,16,20,38 These results suggest that atrophic
changes of muscle fibers could take place in the mus-
cle of the patients with PAOD. Furthermore, there
are studies that report that ischemia may result in a
greater loss of type II fiber than that of type I.12,15
Although no MHC isoforms were investigated at
the protein level in these previous studies, the
atrophic changes of muscle fiber must be linked to
protein metabolism. That is, protein (MHC) break-
down exceeded protein synthesis. Therefore it might
be reasonable to conclude that a decrease of MHC
II is at least partly because of atrophic changes of
muscle in patients with PAOD.
In the present study, the examined individuals
are of relatively advanced age so that age-induced
changes in muscle may be a factor.39-42 Atrophic
changes of muscle fiber may occur in the aging mus-
cle.41,43 By 60 to 70 years of age, muscle mass of
human beings decreases by 25% to 30%.44 In the
aged muscle, type II fibers are more likely to be
reduced.22,41,42 Therefore the age-induced muscle
fiber change may contribute to the decrease of
MHC II. In the present study, age-matched control
patients were enrolled, and the results show that
there was also a significant decrease of MHC II in
patients with PAOD in comparison with the age-
matched control patients. Thus other possible mech-
anisms leading to a decrease of MHC II have to be
considered.
Disuse of muscles in patients with PAOD may
contribute to the changes of MHC isoforms. In
patients with PAOD, the calf muscles are certainly in
disuse, and muscle disuse may lead not only to
atrophic changes of muscle but also to muscle fiber
transition from type I to type II22,24,45 and respec-
tive changes in muscle fiber composition (eg, MHC
isoforms). In the present study, muscle performance
was clearly limited because of insufficient blood sup-
ply to the examined muscle in patients with PAOD
III and IV, and undoubtedly, disuse was common.
However, most of previous studies showed that dis-
use resulted in the decrease of muscle fiber type I,
which is contrary to the results of the present study.
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Table II. Ratios of MHC isoform content: MHC
I/II and MHC IIb/IIa
Subjects n MHC I/II MHC IIa/IIb
Control 5 0.59 ± 0.17 1.87 ± 0.34
PAOD II 3 0.61 ± 0.08 1.88 ± 0.53
PAOD III 3 1.10 ± 0.64 3.31 ± 0.98*
PAOD IV 7 2.36 ± 0.76†‡ 2.44 ± 0.4†§
*P < .05 between control and PAOD III.
†P < .05 between PAOD III and IV.
‡P < .01 between either control or PAOD II and IV.
§P < .05 between control and PAOD IV.
Thus disuse cannot explain the decrease of MHC II
with a relative increase of MHC I because disuse
acts, in part, opposite to the observed effects on
MHC II.
Therefore other mechanisms might be involved
in the decrease of MHC II in patients with PAOD.
Because ischemia in the involved muscle of patients
with PAOD is the major pathophysiologic factor
and ischemia leads to reduced energy content (ie,
decreases in adenylate and creatine pools),19
ischemia in the muscle has an impact on contractile
protein metabolism4 and may lead to muscle fiber
transition and a decrease of MHC II.18,22,27
Tension cost, which represents the energetic effort
in relation to the developed tension, is highest in
type IIb fibers and lowest in type I fibers. This sug-
gests that work efficiency is highest for slow type I
fibers.22,24,29,46 Therefore muscular energy metab-
olism may be more effective under conditions of
very limited blood supply, which gives a physiolog-
ic meaningful explanation for the changes in MHC
isoforms24 from MHC II to MHC I in PAOD III
and IV. The other possible mechanism of the mus-
cle adaptation to ischemia is the change of the task
for the muscle. In patients with PAOD III or IV
and rest pain, the exercise ability is very limited. So,
the ischemic muscles are not used to produce
power, strength, or velocity (hypokinesia and hypo-
dynamia) but to maintain body position (so-called
weight-bearing), which causes changes in neural
activity and increases in slow muscle fibers and
MHC I.22,24 This hypothesis is supported by the
results of the present study that show that no
changes of MHC isoforms were found in the mus-
cle of patients with PAOD II because these patients
can walk regularly.
The limitation of the present study is that the
number of individuals with PAOD is relatively small,
particularly in the subgroups. Because of the impres-
sive differences between the subgroups, we do not
expect substantially different information if more
samples were included. However, further studies
that involve more patients are needed to confirm
these data. In the control group, only a soleus mus-
cle sample could be obtained; however, this was
from the same functional muscle group as the gas-
trocnemius muscle. The results of the soleus muscle
sample were within the range of the other control
samples; therefore it seems to be justified to use the
data. For this reason, the results of this study have to
be interpreted with some caution. Because the
potential changes of myosin isoforms may play an
important role in the muscle performance in patients
with PAOD, further investigation may provide addi-
tional meaningful information.
To date there is no study available to demon-
strate whether there may be a direct effect of
ischemia on muscle fiber distribution or myosin iso-
forms. However, the decrease of MHC II in patients
with PAOD that was demonstrated in this study is
most likely attributed to the effect of ischemia or to
an adaptation to the changed energy metabolism
and/or changed muscle task and is compatible with
muscle fiber transition and fiber type II atrophy.
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